RWLK VS ATRA Stock Comparison

Performance

RWLK
10/100

RWLK returned -33.16% in the last 12 months. Based on SPY's performance of -21.08%, its performance is below average giving it a score of 10 of 100.

ATRA
10/100

ATRA returned -92.95% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

RWLK
80/100

5 analysts offer 12-month price targets for RWLK. Together, they have an average target of 3, the most optimistic target put RWLK at 3 within 12-months and the most pessimistic has RWLK at 3.

ATRA
71/100

6 analysts offer 12-month price targets for ATRA. Together, they have an average target of 3, the most optimistic target put ATRA at 3 within 12-months and the most pessimistic has ATRA at 3.

Sentiment

RWLK
70/100

RWLK had a bullish sentiment score of 69.59% across Twitter and StockTwits over the last 12 months. It had an average of 16.27 posts, 18.18 comments, and 54.60 likes per day.

ATRA
67/100

ATRA had a bullish sentiment score of 67.41% across Twitter and StockTwits over the last 12 months. It had an average of 15.47 posts, 4.74 comments, and 15.89 likes per day.

Technicals

RWLK
10/100

RWLK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

ATRA
14/100

ATRA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

RWLK
10/100

RWLK has missed earnings 12 times in the last 20 quarters.

ATRA
10/100

ATRA has missed earnings 9 times in the last 20 quarters.

Profit

RWLK
10/100

Out of the last 20 quarters, RWLK has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ATRA
10/100

Out of the last 20 quarters, ATRA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

RWLK
44/100

RWLK has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

ATRA
59/100

ATRA has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

All score calculations are broken down here to help you make more informed investing decisions

ReWalk Robotics Ltd Summary

Nasdaq / RWLK

Healthcare

Medical Devices

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.

Atara Biotherapeutics, Inc Summary

Nasdaq / ATRA

Healthcare

Biotechnology

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Power up your portfolio